F 16915,99.39%

产品编号:Bellancom-19886| CAS NO:92510-91-3| 分子式:C28H37NO2| 分子量:419.60

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,

货号 包装 价格 库存与货期 购买量 操作
Bellancom-19886
12520.00 杭州 北京(现货)
Bellancom-19886
20030.00 杭州 北京(现货)
Bellancom-19886
32730.00 杭州 北京(现货)

增值税发票√顺丰快递√订货电话:18601927057

F 16915

产品介绍 F 16915 是二十二碳六烯酸 (DHA,HY-B2167) 的衍生物,也是一种有效的 DHA 前体。F 16915 可预防心力衰竭引起的心房颤动。
生物活性

F 16915, a Docosahexaenoic Acid (DHA, HY-B2167) derivative, is a potent pro-agent of DHA. F 16915 can prevent heart failure-induced atrial fibrillation.

体外研究
体内研究

F 16915 (100 mg/kg; daily oral gavage for 2 months) reduces marked dilation of the left atrial (LA) cavity and the steep decline of left ventricular (LV) contractile function occurring 2 months after infarction and reperfusion in rats.
F 16915 (1-5 g/day for 4 weeks) significantly reduces the infarct size and prevents the left ventricular free wall thinning.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats (220-300 g) with heart failure induced by occlusion of left descending coronary artery and 2 months reperfusion
Dosage: 100 mg/kg
Administration: Daily oral gavage
Result: Reduced the infarct size.
Prevented the left ventricular free wall thinning.
Reduced the de-phosphorylation of connexin43 from atria tissue.
体内研究

F 16915 (100 mg/kg; daily oral gavage for 2 months) reduces marked dilation of the left atrial (LA) cavity and the steep decline of left ventricular (LV) contractile function occurring 2 months after infarction and reperfusion in rats.
F 16915 (1-5 g/day for 4 weeks) significantly reduces the infarct size and prevents the left ventricular free wall thinning.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Sprague-Dawley rats (220-300 g) with heart failure induced by occlusion of left descending coronary artery and 2 months reperfusion
Dosage: 100 mg/kg
Administration: Daily oral gavage
Result: Reduced the infarct size.
Prevented the left ventricular free wall thinning.
Reduced the de-phosphorylation of connexin43 from atria tissue.
性状Oil
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (238.32 mM)

* "≥" means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.3832 mL 11.9161 mL 23.8322 mL
5 mM 0.4766 mL 2.3832 mL 4.7664 mL
10 mM 0.2383 mL 1.1916 mL 2.3832 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

参考文献

相关文档

化学品安全说明书(MSDS)

下载MSDS

质检证书(COA)

相关产品


服务热线

13911702513
18601927057

微信客服